

Please type a plus sign (+) inside this box →

JUL 03 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO
**SUPPLEMENTAL
 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Sheet

1

of

2

Complete if Known

Application Number	09/864,078
Filing Date	23 May 2001
First Named Inventor	Sommadossi, J.-P. et al.
Group Art Unit	1623
Attorney Docket Number	06171.105022

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
JUL 07 2003
TECHNICAL INFORMATION
1623-105022-300

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clmns, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
	A	6,395,716		Novirio Pharmaceuticals Limited	28 May 2002	
	B	6,444,652		Novirio Pharmaceuticals Limited	03 September 2002	
	C	6,340,690		Bio-Chem Pharma, Inc.	02 January 2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	D	WO	00/09531		Novirio Pharmaceuticals Limited	24 February 2000		
	E	WO	01/60315	A3	Shire Biochem Inc.	23 August 2001		
	F	WO	01/90121		Novirio Pharmaceuticals Limited	29 November 2001		
	G	WO	01/91737		Novirio Pharmaceuticals Limited	29 May 2001		
	H	WO	01/92282		Novirio Pharmaceuticals Limited	26 May 2001		
	I	WO	01/96353		Novirio Pharmaceuticals Limited	20 December 2001		
	J	WO	02/057287	A2	Merck & Co. Inc.	25 July 2002		
	K	WO	02/057425	A2	Merck & Co. Inc.	25 July 2002		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2003, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TYPE JC/2003
Submitted for Form 1449/PTO
JUL 03 2003
SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PATENT & TRADEMARK OFFICE

Sheet	2	of	2	Attorney Docket Number	06171.105022
-------	---	----	---	------------------------	--------------

RECEIVED
TECH CENTER 1600
JUL 07 2003
1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number				
L	WO	02/070533		A3	Pharmasset LTD.	12 September 2002	
M	WO	02/094289		A1	F. Hoffmann-La Roche AG	28 November 2002	
N	WO	02/100415		A2	F. Hoffmann-La Roche AG	19 December 2002	
O	WO	02/18404		A2	F. Hoffmann-La Roche AG	07 March 2002	
P	WO	02/32920		A2	Pharmasset LTD.	25 April 2002	
Q	WO	03/026675			Idenix Pharmaceuticals Inc.	03 April 2003	
R	WO	03/26589			Idenix Pharmaceuticals Inc.	03 April 2003	
S	WO	02/48165		A2	Pharmasset LTD.	17 December 2001	
T	WO	01/79246			Pharmasset LTD.	13 April 2001	
U	WO	01/32153			Bio-Chem Pharma, Inc.	03 November 2000	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
V		FRANCESCO <i>et al.</i> , <i>Antiviral Research</i> 58 (2003) 1-16	
W		Oral Session V : Hepatitis C Virus, Flaviviruses	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				Complete If Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/864,078
Sheet	1	of	1	Filing Date	23 May 2001
				First Named Inventor	Sommadossi, J.-P. et al.
				Group Art Unit	1614
				Attorney Docket Number	06171.105022.

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clns, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
	A	2002/0147160	A1	Merck and Co. Inc.	October 10, 2002	
	B	2003/0060400	A1	Novirio (Idenix Pharmaceuticals Inc.)	March 27, 2003	

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ²	Number	Kind Code (if known)			
	C	WO	03/051899 A1	A1	Ribapharm Inc.	26-06-2003	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered. Whether or not citation is in conformance with MPEP 605. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached *Kinds of U.S. Patent Documents*. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.